Nemesis Bioscience Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Out of Business

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Bankr. Admin/​Reorg

Nemesis Bioscience General Information

Description

Developer of anti-microbial therapies designed to inactivate resistance in bacterial pathogens. The company's therapies develop bacterial cybernetics for applications including the reversal of antibiotic resistance and for their clinical, veterinary, and industrial delivery, enabling therapeutics to get existing antibiotics to work again, prevent the spread of resistance genes and so also protect the efficacy of new antibiotics.

Contact Information

Website
www.nemesisbio.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Building B270
  • Babraham Research Campus
  • Cambridge CB22 3AT
  • England, United Kingdom
+44 01223
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • Building B270
  • Babraham Research Campus
  • Cambridge CB22 3AT
  • England, United Kingdom
+44 01223

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nemesis Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Bankruptcy: Admin/Reorg 01-Feb-2023 Completed Bankruptcy: Admin/Reorg
7. Grant 23-Mar-2022 Completed Generating Revenue
6. Later Stage VC 01-Jan-2021 Completed Generating Revenue
5. Grant 27-Mar-2019 Completed Generating Revenue
4. Early Stage VC 15-Jun-2018 Completed Generating Revenue
3. Seed Round 01-Nov-2017 Completed Generating Revenue
2. Grant 01-Aug-2015 $63.3K $465K Completed Startup
1. Seed Round 15-Jun-2015 $465K $465K Completed Startup
To view Nemesis Bioscience’s complete valuation and funding history, request access »

Nemesis Bioscience Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
A Preferred
A Preferred
A Ordinary 3,752 $0.013371 $149.3 $149.3 1x $149.3 6.26%
To view Nemesis Bioscience’s complete cap table history, request access »

Nemesis Bioscience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of anti-microbial therapies designed to inactivate resistance in bacterial pathogens. The company's therapies
Biotechnology
Cambridge, United Kingdom
9 As of 2023

Paris, France
 

Aberdeen, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nemesis Bioscience Competitors (48)

One of Nemesis Bioscience’s 48 competitors is Eligo Bioscience, a Venture Capital-Backed company based in Paris, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Eligo Bioscience Venture Capital-Backed Paris, France
NovaBiotics Venture Capital-Backed Aberdeen, United Kingdom
Venatorx Pharmaceuticals Venture Capital-Backed Malvern, PA
Enterome Venture Capital-Backed Paris, France
Syntara Formerly VC-backed Frenchs Forest, Australia
You’re viewing 5 of 48 competitors. Get the full list »

Nemesis Bioscience Patents

  • 24

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

Nemesis Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2016308591-A1 Delivery vehicle Active 14-Aug-2015
AU-2016308591-B2 Delivery vehicle Inactive 14-Aug-2015
CA-2994506-A1 Delivery vehicle Pending 14-Aug-2015
EP-3334445-A1 Delivery vehicle Inactive 14-Aug-2015
GB-201514510-D0 Delivery vehicle Inactive 14-Aug-2015 A61K35/76
To view Nemesis Bioscience’s complete patent history, request access »

Nemesis Bioscience Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Nemesis Bioscience FAQs

  • When was Nemesis Bioscience founded?

    Nemesis Bioscience was founded in 2014.

  • Where is Nemesis Bioscience headquartered?

    Nemesis Bioscience is headquartered in Cambridge, United Kingdom.

  • What is the size of Nemesis Bioscience?

    Nemesis Bioscience has 9 total employees.

  • What industry is Nemesis Bioscience in?

    Nemesis Bioscience’s primary industry is Biotechnology.

  • Is Nemesis Bioscience a private or public company?

    Nemesis Bioscience is a Private company.

  • What is Nemesis Bioscience’s current revenue?

    The current revenue for Nemesis Bioscience is .

  • How much funding has Nemesis Bioscience raised over time?

    Nemesis Bioscience has raised $3.61M.

  • Who are Nemesis Bioscience’s competitors?

    Eligo Bioscience, NovaBiotics, Venatorx Pharmaceuticals, Enterome, and Syntara are some of the 48 competitors of Nemesis Bioscience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process